TP53 mutations are associated with significantly poorer outcomes in patients with AML/MDS, including inferior remission rates, shorter overall survival, and higher relapse rates relative to patients with wild‐type TP53.3, 4, 5, 6, 7. This evidence concerns the gene TP53 and acute myeloid leukemia.